Spyre Therapeutics, Inc.
SYRE
Price:
$33.51
Market Cap:
$2.02B
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; S...[Read more]
Industry
Biotechnology
IPO Date
2016-04-07
Stock Exchange
NASDAQ
Ticker
SYRE
PE Ratio
[-25.58]
ROE
[-31.18%]
Current Ratio
[10.90]
Dividend Yield
[0%]
Enterprise Value
[1.96B]
Dividend History
The ROE as of December 2025 (TTM) for Spyre Therapeutics, Inc. (SYRE) is -31.18%
According to Spyre Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -31.18%. This represents a change of 306.71% compared to the average of -7.67% of the last 4 quarters.
Spyre Therapeutics, Inc. (SYRE) Historical ROE (quarterly & annually)
How has SYRE ROE performed in the past?
The mean historical ROE of Spyre Therapeutics, Inc. over the last ten years is -84.30%. The current -31.18% ROE has changed -63.02% with respect to the historical average. Over the past ten years (40 quarters), SYRE's ROE was at its highest in in the June 2023 quarter at 104.68%. The ROE was at its lowest in in the March 2023 quarter at -54.74%.
Average
-84.30%
Median
-61.81%
Minimum
-184.11%
Maximum
-31.28%
Spyre Therapeutics, Inc. (SYRE) ROE by Quarter and Year
Discovering the peaks and valleys of Spyre Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 112.55%
Maximum Annual ROE = -31.28%
Minimum Annual Increase = -94.34%
Minimum Annual ROE = -184.11%
| Year | ROE | Change |
|---|---|---|
| 2024 | -40.17% | -78.18% |
| 2023 | -184.11% | 10.50% |
| 2022 | -166.61% | 112.55% |
| 2021 | -78.39% | 35.50% |
| 2020 | -57.85% | -55.58% |
| 2019 | -130.25% | 98.03% |
| 2018 | -65.77% | 21.56% |
| 2017 | -54.11% | 57.02% |
| 2016 | -34.46% | 10.15% |
| 2015 | -31.28% | -94.34% |
Spyre Therapeutics, Inc. (SYRE) Average ROE
How has SYRE ROE performed in the past?
The current ROE of Spyre Therapeutics, Inc. (SYRE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-130.30%
5-year avg
-105.43%
10-year avg
-84.30%
Spyre Therapeutics, Inc. (SYRE) ROE vs. Peers
How is SYRE’s ROE compared to its peers?
Spyre Therapeutics, Inc.’s ROE is greater than Pharvaris N.V. (-69.10%), greater than Immunome, Inc. (-87.36%), greater than Wave Life Sciences Ltd. (-72.94%), greater than Intellia Therapeutics, Inc. (-57.24%), greater than Zymeworks Inc. (-24.48%), greater than Maze Therapeutics, Inc. (-44.62%), greater than AbCellera Biologics Inc. (-16.95%), greater than Upstream Bio, Inc. (-35.90%), greater than Ardelyx, Inc. (-36.91%), greater than Celldex Therapeutics, Inc. (-27.62%),
| Company | ROE | Market cap |
|---|---|---|
| -69.10% | $1.80B | |
| -87.36% | $1.84B | |
| -72.94% | $1.25B | |
| -57.24% | $1.02B | |
| -24.48% | $1.99B | |
| -44.62% | $2.05B | |
| -16.95% | $1.09B | |
| -35.90% | $1.50B | |
| -36.91% | $1.42B | |
| -27.62% | $1.97B |
Build a custom stock screener for Spyre Therapeutics, Inc. (SYRE) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Spyre Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Spyre Therapeutics, Inc. (SYRE) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Spyre Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Spyre Therapeutics, Inc.'s ROE?
How is the ROE calculated for Spyre Therapeutics, Inc. (SYRE)?
What is the highest ROE for Spyre Therapeutics, Inc. (SYRE)?
What is the 3-year average ROE for Spyre Therapeutics, Inc. (SYRE)?
What is the 5-year average ROE for Spyre Therapeutics, Inc. (SYRE)?
How does the current ROE for Spyre Therapeutics, Inc. (SYRE) compare to its historical average?